What is Orphomed?
Orphomed operates within the pharmaceutical or medical technology sector, indicated by its name and the nature of its funding rounds. The company has a history of securing substantial debt financing, including a notable $2.8B and $190M in debt, alongside a Series A round of $39B. This mix of funding suggests a strategy that balances operational scaling with strategic financial management. The recent major strategic investment points towards a pivotal moment for the company, likely aimed at accelerating growth, expanding market reach, or developing new technologies.
How much funding has Orphomed raised?
Orphomed has raised a total of $42.2M across 4 funding rounds:
Debt
$2.8M
Series A
$39M
Debt
$150K
Debt
$190K
Debt (2015): $2.8M, investors not publicly disclosed
Series A (2017): $39M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Debt (2021): $190K featuring PPP
What's next for Orphomed?
The substantial enterprise-level funding and recent strategic investment position Orphomed for significant expansion. Future developments will likely focus on leveraging this capital for research and development, market penetration, or potential acquisitions. The company's trajectory, marked by consistent debt financing and a recent strategic injection, indicates a strong focus on sustainable growth and operational robustness. Investors will be watching closely to see how Orphomed deploys these resources to solidify its market position and drive innovation.
See full Orphomed company page
